Arvinas to Unveil Phase 1 Data for LRRK2 Degrader ARV-102 at AD/PD 2026
Event summary
- Arvinas will present Phase 1 trial data for ARV-102, a PROTAC LRRK2 degrader, at AD/PD 2026 on March 18, 2026.
- ARV-102 is designed to cross the blood-brain barrier and target LRRK2, implicated in Parkinson’s disease (PD) and progressive supranuclear palsy (PSP).
- The presentation will cover safety, pharmacokinetic, and pharmacodynamic data from a Phase 1 trial in PD patients.
- Arvinas plans to initiate a Phase 1b trial for ARV-102 in PSP patients in the first half of 2026, pending regulatory feedback.
The big picture
Arvinas’ presentation of Phase 1 data for ARV-102 at AD/PD 2026 underscores the growing focus on targeted protein degradation as a therapeutic strategy for neurodegenerative diseases. The company’s PROTAC platform positions it at the forefront of innovative drug development, though success will hinge on demonstrating clinical efficacy and navigating regulatory hurdles. The broader biotech sector is watching closely, as breakthroughs in this area could reshape treatment paradigms for conditions like Parkinson’s and PSP.
What we're watching
- Clinical Efficacy
- How the Phase 1 data for ARV-102 will influence investor confidence and regulatory pathways for neurodegenerative disease treatments.
- Pipeline Progression
- Whether Arvinas can sustain momentum in its pipeline, particularly with ARV-102 and other PROTAC-based therapies.
- Market Differentiation
- The pace at which Arvinas can differentiate itself in the competitive landscape of neurodegenerative disease therapies.
Related topics